News & Updates

Alcohol intake tied to lower H. pylori infection risk, with caveat
Alcohol intake tied to lower H. pylori infection risk, with caveat
22 Feb 2023

A recent meta-analysis has revealed a decreased risk of Helicobacter pylori infection among alcohol drinkers as compared with nondrinkers, with wine and mixed types of alcohol showing greater infection reduction than beer.

Alcohol intake tied to lower H. pylori infection risk, with caveat
22 Feb 2023
VV116 noninferior to nirmatrelvir-ritonavir for COVID-19
VV116 noninferior to nirmatrelvir-ritonavir for COVID-19
21 Feb 2023
Is adjunctive vitamin C beneficial to critically ill patients with COVID-19?
Is adjunctive vitamin C beneficial to critically ill patients with COVID-19?
20 Feb 2023 byStephen Padilla

Use of adjunctive intravenous (IV) vitamin C for the management of critically ill patients with COVID-19 infection does not achieve the desired outcome of a reduction in the incidence of mortality, vasopressor requirements, Sequential Organ Failure Assessment (SOFA) scores, or ventilator settings, reports a study.

Is adjunctive vitamin C beneficial to critically ill patients with COVID-19?
20 Feb 2023
Rising cases of community-acquired E. coli UTI in children a cause for concern
Rising cases of community-acquired E. coli UTI in children a cause for concern
18 Feb 2023

A recent study has found an increasing prevalence of community-acquired (CA) urinary tract infection (UTI) by emerging spectrum-β-lactamase-producing (ESBL) E. coli in children, with most isolates showing resistance to multiple drugs.

Rising cases of community-acquired E. coli UTI in children a cause for concern
18 Feb 2023
Counselling, pamphlets boost flu vaccine intake in SG
Counselling, pamphlets boost flu vaccine intake in SG
17 Feb 2023
Shorter treatment regimen feasible for rifampin-resistant TB?
Shorter treatment regimen feasible for rifampin-resistant TB?
13 Feb 2023 byAudrey Abella

Individuals with rifampin-resistant tuberculosis (RR-TB) may have the option to undergo shorter treatment periods, as findings from the phase II/III TB-PRACTECAL* trial show the noninferiority and superiority of a 24-week, all-oral regimen to standard of care (SoC). It also had a better safety profile than SoC.

Shorter treatment regimen feasible for rifampin-resistant TB?
13 Feb 2023